RxDoctor Payments Data

Charles Jackson, MD

Urology · Fayetteville, ARNPI 1255659082

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,964 of the $8,734 with a category attached, or 68.3%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.7%.

$8,734in general payments, 2019–2025

Across 213 payments — averaging $41.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Axonics, Inc.$2K
  • Teleflex LLC$770
  • Coloplast$670
  • Medtronic$608
  • Boston Scientific$600
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$2,42128%
  • Food & beverage$5,96468%
  • Education$3504%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,734 in reported general payments places this provider in the 60th percentile of 88 urology providers in Arkansas.

See all urology providers in Arkansas

Medicare billing

Part B allowed, 2024
$288,441
Medicare patients
897
Services billed
7,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron154$97,880
GemtesaVibegron30$21,021
Tamsulosin Hcl923$12,343
Finasteride699$8,271
Mirabegron ErMirabegron11$5,432
Oxybutynin Chloride365$4,093
JardianceEmpagliflozin13$3,905
Potassium Citrate ErPotassium Citrate30$2,992
Estradiol40$2,620
Silodosin33$2,339
Dutasteride23$1,453
Trimethoprim15$1,395
Testosterone Cypionate38$1,128
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$960
CefuroximeCefuroxime Axetil52$934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$488$97,880154 claims
Sumitomo Pharma America, Inc.Gemtesa$280$21,02130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 urology providers in Arkansas.

Other urology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →